Formoflo-G MDI launched in India, world's first fixed-dose triple combination drug for COPD management
Lupin has launched Formoflo-G® MDI in India, described as the world's first fixed-dose triple combination metered-dose inhaler for COPD.
- Product Launched
- Formoflo-G® MDI in India
- Regulatory Approval
- Drug Controller General of India (DCGI)
- India Respiratory Therapy Segment Rank
- #2 (IQVIA, MAT Mar 2026)
Lupin has launched Formoflo-G® MDI in India, which the company describes as the world's first fixed-dose triple combination metered-dose inhaler (MDI) for chronic obstructive pulmonary disease (COPD). The launch follows approval from the Drug Controller General of India (DCGI).
What has been launched
- Formoflo-G® is a metered-dose inhaler that brings three established therapies together in a single inhaler: Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate.
- It is indicated for the long-term management and treatment of moderate to severe COPD.
- It is available as a twice-daily, single-strength fixed dose.
Why the company sees this as significant
- COPD is described as a condition that remains a leading cause of death and disability, with more than 55 million people living with it in India.
- The company says the launch expands treatment options for patients living with COPD and reflects its focus on unmet patient needs through differentiated, high-quality therapies.
What the management said
Nilesh Gupta, Managing Director, said access to effective therapies remains critical as respiratory diseases continue to impact millions across India, and that the product reflects the company's commitment to addressing unmet patient needs. Rajeev Sibal, President - India Region Formulations, said the product brings three established therapies into a single inhaler, strengthens Lupin's respiratory portfolio and provides healthcare professionals with an important treatment option for appropriate COPD patients.
The company's respiratory position
- Lupin is ranked #2 in the respiratory therapy segment in India (IQVIA, MAT Mar 2026).
About the company, as stated in the release
- A global pharmaceutical company headquartered in Mumbai.
- Products distributed in over 100 markets.
- 15 state-of-the-art manufacturing facilities and 6 research centres.
- A workforce of over 26,000 professionals.
What this announcement is
The disclosure is a press release informing the exchanges of a product launch in India, setting out the product, the indication it is used for, the dosing form and the company's position in the Indian respiratory therapy segment.
Also from Lupin
Philippines Arm Completes Buyback of 30,559 Shares, Becomes Step-Down Wholly Owned Subsidiary
1 Oct 2026
Tentative U.S. FDA Approval for Novel Apixaban Oral Suspension 1.25 mg/mL
28 Sep 2026
More numbers
- People living with COPD in Indiamore than 55 million
- Lupin's rank in India respiratory therapy segment (IQVIA, MAT Mar 2026)#2
- Markets where products are distributedover 100 markets
- State-of-the-art manufacturing facilities15
- Research centers6
- Workforce strengthover 26,000
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.